Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24510024 | 0.84 | PDE2A (0.36) | PDE2AALOX5APFEN1KCNN4HRH4 | |
| SCHEMBL22978515 | 0.81 | P2RX3 (0.37) | ALOX5APFEN1 | |
| SCHEMBL22978698 | 0.79 | PTGS1 (0.35) | HRH4 | |
| SCHEMBL24509375 | 0.79 | GRIN1 (0.33) | PDE2AIDH1 | |
| SCHEMBL27892094 | 0.76 | NAAA (0.41) | PDE2AALOX5APFEN1 | |
| SCHEMBL24510122 | 0.75 | ACACB (0.34) | FEN1 | |
| SCHEMBL24510022 | 0.74 | ALOX5AP (0.33) | PDE2AALOX5APFEN1KCNN4 | |
| SCHEMBL13073948 | 0.73 | PDE2A (0.38) | PDE2AALOX5APFEN1KCNN4HRH4 | |
| SCHEMBL18933646 | 0.70 | PDE2A (0.44) | PDE2AKCNN4HRH4 | |
| SCHEMBL24510025 | 0.68 | EPHX2 (0.39) | PDE2AKCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101535-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2024-03-28 | — | — | US | disclosed |
| EP-4261211-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2023-10-18 | — | — | EP | disclosed |
| EP-4261211-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2023-10-18 | — | — | EP | disclosed |
| CN-116783188-A | Dihydro-isoquinolone derivative and application thereof | 上海奕拓医药科技有限责任公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2022122037-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | 上海奕拓医药科技有限责任公司 | 2022-06-16 | — | — | WO | disclosed |
| WO-2022122037-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | 上海奕拓医药科技有限责任公司 | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101535-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | WDR5, WDR1, WDR77 | PDE2A 4385/4885ALOX5AP 2544/4885FEN1 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.